Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 200

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 200
---
30,2025202420252024Cost of goods sold$1,506 $1,509 $4,904 $3,896 Research and development2,326 1,794 6,974 5,522 Selling, general and administrative10,146 9,137 32,125 25,970 Contingent consideration charges (gains), acquisition-related expenses, restructuring and other— 790 — 3,517         Total$13,978 $13,230 $44,003 $38,905 Stock-based compensation from:    Stock options$3,403 $4,767 $12,152 $17,292     Restricted stock units10,383 8,276 30,670 21,003     Employee stock purchase plan share options192 187 1,181 610         Total$13,978 $13,230 $44,003 $38,905 Equity AwardsThe following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the nine months ended September 30, 2025:Stock Options Number of Stock Options Weighted Average Exercise Price (Per Share) Outstanding at December 31, 20246,845,618 $42.95      Granted485,232 25.30      Exercised(726)15.14      Forfeited(202,193)42.18      Expired(676,528)52.13  Outstanding at September 30, 20256,451,403 40.68 Restricted Stock Units Number of Restricted Stock Units Weighted Average Grant Date Fair Value (Per Share)Unvested at December 31, 20242,769,728 $32.07      Granted2,449,865 26.00      Vested(766,373)36.67      Forfeited(239,411)28.45 Unvested at September 30, 20254,213,809 27.82 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  27

The weighted average fair value of stock options granted during the nine months ended September 30, 2025 was $13.73 per share.